Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ARV-393 in Cancer, B-cell lymphoma, Blood cancer. The expected timing is based on the latest available company guidance and may change.
1/10/25- Present initial data in 2025. 6/13/25- Preclinical data presented at EHA'25. 11/05/25:- Early Ph1 NHL responses observed; dose escalation ongoing. Updated Ph1 data and combo DLBCL trial planned 2026. 02/24/26:- Ongoing Ph1 NHL trial shows multiple early responses; glofitamab combo cohort enrollment planned H1 2026; updated data expected H2 2026. 05/12/26:- Initiated ARV-393 plus glofitamab Phase 1 DLBCL cohort; NHL monotherapy dose escalation ongoing; multiple early responses; updated data H2 2026. 08/04/26:- Ph1 NCT06393738 data due H2 2026; monotherapy and glofitamab updates due Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.